无血液培养基分离嗜血杆菌的方法学研究

目的评价自制不加血液的培养基和传统的羊血巧克力培养基分离嗜血杆菌的效果。方法将流感嗜血杆菌ATCC10211接种于无血液培养基和传统培养基上,计算和比较两种培养基上嗜血杆菌的平均生长指数,并用此两种培养基对225份临床痰标本进行嗜血杆菌的分离,比较两种培养基上嗜血杆菌的分离率。结果无血液培养基与传统巧克力培养基的平均生长指数分别为11.06、8.05,225份痰标本中嗜血杆菌的分离率分别为20%、11.6%,两者有显著性差异(P<0.01)。结论无血液培养基分离嗜血杆菌的方法简便、实用、效果较好,有应用推广价值。     

乙型肝炎免疫球蛋白聚氰基丙烯酸正丁酯纳米粒抑制HBsAg、HBV DNA分泌的体外实验

Objective To investigate the inhibitive activities of hepatitis B immunoglobulin(HBIG)poly(butylcynaoacrylate)nanoparticles(HBIG-PBCA-NP)to hepatitis B surface antigen(HBsAg)and hepatitis B virus(HBV)DNA secretions using HBV infected cell model in vitro.Methods HepG 2.2.15 cells were cultured with media containing HBIG-PBCA-NP or HBIG for several days,or cultured with HBIG-PBC-NP and HBIG for 2 days and without HBIG-PBCA-NP and HBIG from day 3.The supernatants at different time points were collected for quantitative detection of HBsAg and HBV DNA.The comparisons between groups were done by variance analysis.Resalts Secretions of HBsAg and HBV DNA in supernatants of HepG2.2.15 cultured with 0.1-10.0 IU/mL of HBIG-PBCA-NP and HBIG were inhibited significantly compared with control group.HBsAg titers and HBV DNA levels in supernatants of HBIG-PBCA-NP group and HBIG group cultured with media without HBIG-PBCA-NP and HBIG kept decreasing at day 5 and 7,then rebounded at day 9 and 11.HBsAg titera in supernatants of 0.1,1.0,5.0 IU/mL HBIG-PBCA-NP group were all significantly different from those in HBIG group at day 9[(31.31±1.98)μg/L vs(40.62±2.99)μg/L,(23.79±1.31)μg/L vs(36.51±2.12)μg/L,(19.91±1.74)μg/L vs(33.03±1.65)μg/L;F=412.24,P＜0.01].Couclusion HBIG-PBCA-NP can inhibit secretions of HgsAg and HBV DNA in vitro,which is more effective than HBIG.     

乙型肝炎免疫球蛋白聚氰基丙烯酸正丁酯纳米粒抑制HBsAg、HBV DNA分泌的体外实验

Objective To investigate the inhibitive activities of hepatitis B immunoglobulin(HBIG)poly(butylcynaoacrylate)nanoparticles(HBIG-PBCA-NP)to hepatitis B surface antigen(HBsAg)and hepatitis B virus(HBV)DNA secretions using HBV infected cell model in vitro.Methods HepG 2.2.15 cells were cultured with media containing HBIG-PBCA-NP or HBIG for several days,or cultured with HBIG-PBC-NP and HBIG for 2 days and without HBIG-PBCA-NP and HBIG from day 3.The supernatants at different time points were collected for quantitative detection of HBsAg and HBV DNA.The comparisons between groups were done by variance analysis.Resalts Secretions of HBsAg and HBV DNA in supernatants of HepG2.2.15 cultured with 0.1-10.0 IU/mL of HBIG-PBCA-NP and HBIG were inhibited significantly compared with control group.HBsAg titers and HBV DNA levels in supernatants of HBIG-PBCA-NP group and HBIG group cultured with media without HBIG-PBCA-NP and HBIG kept decreasing at day 5 and 7,then rebounded at day 9 and 11.HBsAg titera in supernatants of 0.1,1.0,5.0 IU/mL HBIG-PBCA-NP group were all significantly different from those in HBIG group at day 9[(31.31±1.98)μg/L vs(40.62±2.99)μg/L,(23.79±1.31)μg/L vs(36.51±2.12)μg/L,(19.91±1.74)μg/L vs(33.03±1.65)μg/L;F=412.24,P＜0.01].Couclusion HBIG-PBCA-NP can inhibit secretions of HgsAg and HBV DNA in vitro,which is more effective than HBIG.     

联合检测超敏C-反应蛋白与心型脂肪酸结合蛋白在总胆固醇正常的冠心病诊断中的应用

目的探讨联合检测超敏C-反应蛋白（hs-CRP）和心型脂肪酸结合蛋白（h-FABP）对总胆固醇正常的冠心病（CHD）的诊断价值。方法对50例正常对照者（对照组）和130例CHD患者（CHD组）血清中hs-CRP和h-FABP进行测定。结果总胆固醇正常、边缘性增高和升高的CHD患者血清中hs-CRP和h-FABP均显著高于正常对照组（P〈0．01）。联合应用hs-CRP和h-FABP两种标志物判别，对总胆固醇正常的CHD患者诊断阳性率为90．0％，分别高于单独应用hs-CRP的75．0％和h-FABP的32．5％。结论联合检测hs-CRP和h-FABP，既能提高预测发生CHD的危险性，也可提高早期诊断CHD和心肌损伤的准确性。     

铜绿假单胞菌对耐喹诺酮药物质粒基因的研究

目的：探讨铜绿假单胞菌对喹诺酮类药物的耐药质粒与周围共生菌耐药质粒染色体相互转移的关系。方法收集深圳市第七人民医院2011年1月～2013年12月481份各种样品培养出的铜绿假单胞菌31例,药敏实验结果对喹诺酮耐药的15例为研究对象,运用质粒转化、提取实验证实其耐药质粒的存在,PCR扩增、基因序列分析,与周围共生菌耐药质粒的基因序列比对。结果铜绿假单胞菌耐药株的耐药质粒与周围共生菌质粒发现有相同基因序列（χ2检验,χ2＝1.207,P＜0.01）。结论耐药质粒能在不同种属细菌之间传递。     

电化学发光免疫分析法定量测定HBsAg最适稀释度的研究

目的:探讨电化学发光免疫分析法(ECLIA)定量测定HBsAg的最适稀释度.方法:采用正常混合血清倍比稀释HBsAg( )/HBeAg( )/HBcAb( )、HBsAg( )/HBeAb( )/HBcAb( )和HBsAg( )/HBcAb( )三种模式血清,应用ECLIA夹心法定量测定其HBsAg的含量.结果:ECLIA法定量测定HBsAg阳性的三种血清学模式血清稀释度不同,HBsAg( )/HBeAg( )/HBcAb( )模式存在HD-HOOK效应,其最适稀释度为1:32;HBsAg( )/HBeAb( )/HBcAb( )和HBsAg( )/HBcAb( )模式不需进行稀释,原倍血清HBsAg测定值最高.结论:利用ECLIA法定量测定HBsAg( )/HBeAg( )/HBcAb( )模式血清中HBsAg时,应对其血清进行预稀释,同时测定原倍和1:32稀释血清HBsAg含量,根据测定情况计算其结果,而HBsAg( )/HBeAb( )/HBcAb( )和HBsAg( )/HBcAb( )模式,其血清HBsAg测定一般不需进行预稀释.     

急性脑出血患者血清甲状腺激素水平的变化及其临床意义

目的探讨急性脑出血患者血清甲状腺激素水平及其临床意义。方法根据脑出血量多少、神经功能缺损程度及治疗2周后的疗效,将98例急性脑出血患者分为:脑出血量≤30ml为A组、>30ml为B组;神经功能缺损程度轻型的为C组、中型的为D组、重型的为E组;疗效为显效的为F组、有效的为G组、无效的为H组。选择40例健康者作对照。采用电化学发光法检测急性脑出血患者和健康对照者血清中T3、T4、FT3、FT4、TSH水平。结果急性脑出血患者A、B、C、D、E、G和H组与健康对照组,B组与A组,D、E组与C组,G、H组与F组之间,甲状腺激素水平差异均有统计学意义(P<0.05),T4、FT4、TSH水平升高,而T3、FT3水平下降。而疗效为显效的F组与健康对照组比较,甲状腺激素水平差异无统计学意义(P>0.05)。结论急性脑出血患者T4、FT4、TSH水平升高和T3、FT3水平下降与病情的严重程度及预后密切相关。     

电化学发光法HBsAg定量分析最适稀释度及其与HBV-DNA含量关系的探讨

目的:探讨电化学发光免疫分析法(ECLIA)常见血清学模式HBsAg定量分析最适稀释度及其与HBV-DNA含量的关系。方法:采用正常混合血清倍比稀释HBsAg(+)/HBeAg(+)/HBcAb(+)、HBsAg(+)/HBeAb(+)/HBcAb(+)和HBsAg(+)/HBcAb(+)三种模式血清,ECLIA夹心法定量测定原倍及稀释血清HBsAg的浓度,荧光定量PCR测定其HBV-DNA含量(结果以对数值表示)。结果:HBsAg阳性的三种血清学模式血清最适稀释度不同,HBsAg(+)/HBeAg(+)/HBcAb(+)模式存在HD-HOOK效应,其最适稀释度为1∶32,HBsAg测定结果与HBV-DNA含量分析无显著性相关(r=0.235,P>0.05)。HBsAg(+)/HBeAb(+)/HBcAb(+)和HBsAg(+)/HBcAb(+)模式原倍血清HBsAg测定值最高,不需进行稀释,HBsAg测定结果与HBV-DNA定量分析呈正相关(r分别为0.982,0.968;P均<0.01)。结论:ECLIA法定量测定HBsAg(+)/HBeAg(+)/HBcAb(+)模式血清中HbsAg时,应参照HBV-DNA含量分析,对其血清进行预稀释,同时测定原倍和1∶32稀释血清HBsAg含量。而HBsAg(+)/HBeAb(+)/HBcAb(+)和HBsAg(+)/HBcAb(+)模式,不需进行预稀释,其血清HBsAg结果与HBV-DNA含量变化一致。     

血吸虫糖蛋白研究进展

本概述了糖蛋白在血吸虫病疫苗研究中的进展，主要阐述了糖蛋白的一般特性，免疫学特征及几种血吸虫疫苗相关的糖蛋白研究现状。